A new approach for prediction of tumor sensitivity to targeted drugs based on functional data

BMC Bioinformatics

Volumn 14, Issue 1, 2013, Pages

  Berlow, Noah ^a   Davis, Lara E ^b   Cantor, Emma L ^b   Séguin, Bernard ^c   Keller, Charles ^b   Pal, Ranadip ^a  

^a Department of Electrical and Computer Engineering   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG-PROTEIN INTERACTIONS; FUNCTIONAL PERTURBATION; GENETIC CHARACTERIZATION; LEAVE-ONE-OUT CROSS VALIDATIONS; PREDICTION ACCURACY; SENSITIVITY PREDICTION; SMALL-MOLECULE DRUGS; THERAPEUTIC STRATEGY;

DISEASES; FORECASTING;

TUMORS;

ANTINEOPLASTIC AGENT;

ALGORITHM; ANIMAL; CELL SURVIVAL; DOG; DRUG SCREENING; GENE REGULATORY NETWORK; GENETICS; HUMAN; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PROCEDURES; TUMOR CELL CULTURE; ARTICLE; METHODOLOGY; NEOPLASM;

ALGORITHMS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; DOGS; DRUG SCREENING ASSAYS, ANTITUMOR; GENE REGULATORY NETWORKS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 84880861643     PISSN: None     EISSN: 14712105     Source Type: Journal    
DOI: 10.1186/1471-2105-14-239     Document Type: Article

References (38)

1. Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008, 112(13):4808-17.
2. Sawyers C. Targeted cancer therapy. Nature 2004, 432:294-297.
3. Green MR. Targeting targeted therapy. New England J Med 2004, 350:2191-2193.
4. Druker BJ. Molecularly targeted therapy: have the floodgates opened?. Oncologist 2004, 9:357-360.
5. Hopkins A, Mason J, Overington J. Can we rationally design promiscuous drugs?. Curr Opin Struct Biol 2006, 16:127-136.
6. Knight ZA, Shokat KM. Features of selective kinase inhibitors. Chem Biol 2005, 12(6):621-637.
7. Sos ML, et al. Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest 2009, 119(6):1727-1740.
8. Molinari F, Felicioni L, Buscarino M, De Dosso S, Buttitta F, Malatesta S, Movilia A, Luoni M, Boldorini R, Alabiso O, Girlando S, Soini B, Spitale A, Di Nicolantonio F, Saletti P, Crippa S, Mazzucchelli L, Marchetti A, Bardelli A, Frattini M. Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clin Cancer Res 2011, 17(14):4901-4914.
9. Staunton JE, et al. Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci 2001, 98:10787-10792.
10. Lee JK, Havaleshko DM, Cho H, Weinstein JN, Kaldjian EP, Karpovich J, Grimshaw A, Theodorescu D. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci 2007, 104(32):13086-13091.
11. Riddick G, Song H, Ahn S, Walling J, Borges-Rivera D, Zhang W, Fine HA. Predicting in vitro drug sensitivity using random forests. Bioinformatics 2011, 27(2):220-224.
12. Venkatesan K, Stransky N, Margolin A, Reddy A, Raman P, Sonkin D, Jones M, Wilson C, Kim S, Warmuth M, Sellers W, Lehar J, Barretina J, Caponigro G, Garraway L, Morrissey M. Prediction of drug response using genomic signatures from the Cancer Cell Line Encyclopedia. AACR Meet Abstr 2010, 2010:PR2. http://www.aacrmeetingabstracts.org.
13. Mitsos A, Melas IN, Siminelakis P, Chairakaki AD, Saez-Rodriguez J, Alexopoulos LG. Identifying drug effects via pathway alterations using an integer linear programming optimization formulation on phosphoproteomic data. PLoS Comput Biol 2009, 5(12):e1000591+. http://dx.doi.org/10.1371/journal.pcbi.1000591.
14. Walther Z, Sklar J. Molecular tumor profiling for prediction of response to anticancer therapies. Cancer J 2011, 17(2):71-9.
15. Barretina J, et al. The cancer cell line encyclopedia enables Predictive modelling of anticancer drug sensitivity. Nature 2012, 483(7391):603-607. [http://dx.doi.org/10.1038/nature11003].
16. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, Faraoni R, Floyd M, Hunt JP, Lockhart DJ, Milanov ZV, Morrison MJ, Pallares G, Patel HK, Pritchard S, Wodicka LM, Zarrinkar PP. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008, 26:127-132.
17. Pal R, Berlow N, Haider S. Anticancer drug sensitivity analysis: an integrated approach applied to Erlotinib sensitivity prediction in the CCLE database. IEEE International Workshop on Genomic Signal Processing and Statistics (GENSIPS) 2012, 9-12. Washington DC.
18. Tyner JW, Deininger MW, Loriaux MM, Chang BH, Gotlib JR, Willis SG, Erickson H, Kovacsovics T, O'Hare T, Heinrich MC, Druker BJ. RNAi screen for rapid therapeutic target identification in leukemia patients. Proc Natl Acad Sci U S A 2009, 106(21):8695-8700.
19. Richmond A, Su Y. Mouse xenograft models vs GEM models for human cancer therapeutics. Dis Model Mech 2008, 1(2-3):78-82.
20. Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B, Karaman MW, Pratz KW, Pallares G, Chao Q, Sprankle KG, Patel HK, Levis M, Armstrong RC, James J, Bhagwat SS. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood 2009, 114(14):2984-2992.
21. Andreassen A, Oyjord T, Hovig E, Holm R, Florenes V, et al. p53 abnormalities in different subtypes of human sarcomas. Cancer Res 1993, 53(3):468-471.
22. Kansara M, Thomas DM. Molecular pathogenesis of osteosarcoma. DNA Cell Biol 2007, 26:1-18.
23. Overholtzer M, Rao PH, Favis R, Lu XY, Elowitz MB, Barany F, Ladanyi M, Gorlick R, Levine AJ. The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability. Proc Natl Acad Sci 2003, 100(20):11547-11552.
24. Benassi MS, Molendini L, Gamberi G, Ragazzini P, Sollazzo MR, Merli M, Asp J, Magagnoli G, Balladelli A, Bertoni F, Picci P. Alteration of pRb/p16/cdk4 regulation in human osteosarcoma. Int J Cancer 1999, 84(5):489-493.
25. Besson A, Yong VW. Involvement of p21Waf1 Cip1 in protein kinase C alpha induced cell cycle progression. Mol Cell Biol 2000, 20(13):4580-90.
26. Shapovalov Y, Benavidez D, Zuch D, Eliseev RA. Proteasome inhibition with bortezomib suppresses growth and induces apoptosis in osteosarcoma. Int J Cancer 2010, 127:67-76.
27. Scheffner M. Ubiquitin, E6-AP, and their role in p53 inactivation. Pharmacol Ther 1998, 78(3):129-139.
28. Zhang W, Lee JC, Kumar S, Gowen M. ERK pathway mediates the activation of Cdk2 in IGF1 induced proliferation of human osteosarcoma MG63 cells. J Bone Miner Res 1999, 14(4):528-535.
29. Choy E, Hornicek F, MacConaill L, Harmon D, Tariq Z, Garraway L, Duan Z. High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes. Cancer 2012, 118(11):2905-2914.
30. Morgensztern D, McLeod H. PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 2005, 16(8):797-803.
31. Robin P, Boulven I, Desmyter C, Harbon S, Leiber D. ET1 stimulates ERK signaling pathway through sequential activation of PKC and Src in rat myometrial cells. Am J Physiol - Cell Physiol 2002, 283:C251-C260.
32. Kanehisa M, Goto S. KEGG: Kyoto Encycolpedia of Genes and Genomes. Nucleic Acids Res 2000, 28:27-30.
33. Pubchem [Library containing dissociation constants of Drugs]. http://pubchem.ncbi.nlm.nih.gov/, Pubchem.
34. Pal R, Berlow N. A Kinase inhibition map approach for tumor sensitivity prediction and combination therapy design for targeted drugs. Pacific Symposium on Biocomputing 2012, 351-62. http://psb.stanford.edu/psb-online/proceedings/psb12/pal.pdf.
35. Pudil P, Novovicova J, Kittler J. Floating search methods in feature selection. Pattern Recog Lett 1994, 15:1119-1125.
36. Kauffman S. The Origins of Order: Self-Organization and Selection in Evolution 1993, New York: Oxford Univ. Press.
37. Pal R, Datta A, Dougherty ER. Robust intervention in probabilistic boolean networks. IEEE Trans Signal Process 2008, 56:1280-1294.
38. Pal R, Datta A, Dougherty ER. Bayesian robustness in the control of gene regulatory networks. IEEE Trans Signal Process 2009, 57:3667-3678.